developed for the treatment of moderate-to-severe vasomotor symptoms associated with menopause
is a nonhormonal, selective neurokinin 3 receptor antagonist that blocks neurokinin B binding on the kisspeptin/neurokinin B/dynorphin neurons in the hypothalamus to moderate neuronal activity in the thermoregulatory center
is a once-daily oral nonhormonal therapy
a review (n=2168;5 RCTs) found fezolinetant is effective in lowering moderate-to-severe vasomotor symptom frequency (pooled mean difference of 2.62 [95% CI 1.84-3.41] episodes per day versus placebo) and was associated with improvement in sleep quality (3)
possible adverse effects of fezolinetant include diarrhoea, insomnia, abdominal pain and an increase in alanine transaminase (4)
Reference:
Neal-Perry G, Cano A, Lederman S, Nappi RE, Santoro N, Wolfman W, English M, Franklin C, Valluri U, Ottery FD. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial. Obstet Gynecol. 2023 Apr 1;141(4):737-747
Wright AC, Beaudoin FL, McQueen RB, Yeung K, Moradi A, Herron-Smith S, Gutierrez E, Lin GA, Pearson SD. The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council. J Manag Care Spec Pharm. 2023 Jun;29(6):692-698.
Bonga KN et al. Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis. Obstetrics & Gynecology ():10.1097/AOG.0000000000005508, January 16, 2024.
Fezolinetant for menopausal vasomotor symptomsDrug and Therapeutics Bulletin 2024;62:118-124
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.